Prospect

Researchers are evaluating the PAVE (Parallactic Visual-Field Enhancement) System to treat chronic visual field loss caused by stroke, traumatic brain injury, or brain surgery. This study focuses on patients with lasting visual field defects such as homonymous hemianopia or quadrantanopia, at least six months after the brain injury and up to ten years after onset. The main goal is to see if the PAVE therapy can improve the area of the visual field using virtual reality stimulation. The PAVE treatment uses a virtual reality headset to deliver visual stimulation three times per week for eight weeks, with each session consisting of two 7-minute therapy periods separated by a short break. Participants receive the therapy either at the clinic or at home. Visual field assessments are done before and after each therapy session to measure changes. Participants will visit the clinic at the start for baseline measurements and then again at four and eight weeks for follow-up visual field tests and a visual function questionnaire. A final visit occurs four weeks after therapy ends to assess lasting effects. Researchers will track changes in visual field area using Goldmann-type kinetic perimetry and collect patient-reported visual function data to evaluate the therapy's impact.